INTRODUCTION
Recent progress, following the introduction of molecular genetics methods, has permitted the identification of some of the genes which might be involved in the initiation and progression of tumorigenesis.
Some of these genes are cellular genes, the proto-oncogenes, which normally function in the regulation of cellular proliferation and differentiation. Through alterations in the regulation of their expression and/or in their coding sequences, these proto-oncogenes are activated into oncogenes, whose persistent expression contributes to the tumorigenic phenotype in a dominant manner.
The study of some cancers, which can occur in hereditary forms, has led to the identification of another class of genes, whose alterations appear to be equally important in tumorigenesis. These so-called anti-oncogenes or tumor suppressor genes or recessive oncogenes are probably implicated in a negative regulation of cellular proliferation. Their normal activity therefore tends to limit cell growth and it is the loss of this activity which indeed contributes to tumorigenesis. The (Slamon et al, 1987; Guérin et al, 1988; King et al, 1989; Tsuda et al, 1989; Wright et al, 1989 al, 1987) or in the regulation of gene expression (Kingston et al, 1984) at the transcriptional (Onclerq et al, 1988) or post-transcriptional level (Prendergast and Cole, 1989) .
Little is known about the precise pathways through which the signals transduced through the plasma membrane by membrane receptors are transmitted to the nucleus to activate gene expression and DNA replication. Protein kinases located in the cytoplasm are probably involved and one good candidate is the product of the craf proto-oncogene, which encodes such a serine-threonine protein kinase. Recent data (Morrison et al, 1988; Wasylyk et al, 1989) show that its kinase activity is increased in response to growth factor stimulation and that the expression of the raf oncogene activates transcription from promoter elements recognized by the products of the nuclear proto-oncogenes c-junl c-fos.
Several proto-oncogenes code for proteins which bind to the cytoplasmic side of the plasma membrane, after posttranslational addition to their peptide structure of a hydrophobic chain (Buss and Sefton, 1985; Hancock et al, 1989 (Stanbridge, 1987) . The tumorigenic phenotype in these experiments is therefore recessive and the normal cell is supposed to express genes, which suppress the tumorigenic phenotype.
Evidence has been accumulating in recent years to the effect that the proliferation of normal cells is regulated by cytokines, some of which stimulate cell division while others exert a negative effect on cell growth (Sporn and Roberts, 1988 (Ludlow et al, 1989 (Lee et al, 1988; TAng et al, 1988 (Eliyahu et al, 1984; Parada et al, 1984) . However, it was recently discovered that the particular p53 cDNA clone used in co-transformation experiments was a mutated form of the normal gene, which is itself devoid of co-operating activity (Hinds et al, 1989 (Wolf and Rotter, 1985; Masuda et al, 1987; Ben-David et al, 1988; Hicks and Mowat, 1988) and it has already been known for several years that p53 forms complexes with SV40 large T (Lane and Crawford, 1979) and adenovirus 5 E1 B (Sarnow et al, 1982) (Miller et al, 1986) is in fact an anti-oncogene and not a protooncogene (Finlay et al, 1989) . If (Baker et al, 1989) .
Colorectal cancer is a good example of a common human tumor, for which the respective contributions of oncogene activation and allele losses to tumor progression have been carefully studied (Vogelstein et al, 1988 
